Tu et al. demonstrated that the downregulation of human histocompatibility leukocyte antigen (HLA) complex P5 (HCP5), which targets miR-101, inhibits osteosarcoma cell proliferation, migration, and invasion via the competitive binding of miR-101 to EPHA7 [118]. This evidence concerns the gene HCP5 and osteosarcoma.